GILEAD SCIENCES, INC. (GILD)

↓ Download CSV

CIK 0000882095 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, GILEAD SCIENCES, INC. reported revenue of $29.44B, up 2.4% from the prior year. The company was profitable, with a net margin of 28.9%.

Key ratios (FY2025)

34.0%
Operating margin
28.9%
Net margin
37.6%
Return on equity
+2.4%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$29.44B$28.75B$27.12B$27.28B$27.30B$24.69B$22.45B$22.13B$26.11B$30.39B
Cost of Revenue$6.23B$6.25B$6.50B$5.66B$6.60B$4.57B$4.67B$4.85B$4.37B$4.26B
Operating Income$10.02B$1.66B$7.61B$7.33B$9.92B$4.07B$4.29B$8.20B$14.12B$17.63B
Net Income$8.51B$480.00M$5.67B$4.59B$6.22B$123.00M$5.39B$5.46B$4.63B$13.50B
EPS (Diluted)$6.78$0.38$4.50$3.64$4.93$0.10$4.22$4.17$3.51$9.94
Total Assets$59.02B$58.99B$62.12B$63.17B$67.95B$68.41B$61.63B$63.67B$70.28B$56.98B
Shareholders' Equity$22.62B$19.25B$22.75B$21.21B$21.06B$18.22B$22.65B$21.53B$20.50B$19.36B
Cash & Equivalents$5.41B$5.34B$6.00B$11.63B$17.94B$7.59B$8.23B
Operating Cash Flow$10.02B$10.83B$8.01B$9.07B$11.38B$8.17B$9.14B$8.40B$11.90B$17.05B
Capital Expenditures$563.00M$523.00M$585.00M$728.00M$579.00M$650.00M$825.00M$924.00M
Shares Outstanding1.25B1.25B1.26B1.26B1.26B1.26B1.28B1.31B1.32B1.36B
Dividends Per Share$3.16$3.08$3.00$2.92$2.84$2.72$2.52$2.28$2.08$1.84